DXCM Quote, Financials, Valuation and Earnings

Orthofix Medical has a net margin of 13.54% compared to DexCom's net margin of -13.93%. DexCom's return on equity of 30.96% beat Orthofix Medical's return on equity of -20.83%.

DexCom has a consensus price target of $95.68, signalling upside risk potential of 20.51%. On the other hand Orthofix Medical has an analysts' consensus of -- which suggests that it could grow by 39.99%. Given that Orthofix Medical has higher upside potential than DexCom, analysts believe Orthofix Medical is more attractive than DexCom.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.972%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Orthofix Medical quarterly revenues of $196.6M. DexCom's net income of $134.6M is higher than Orthofix Medical's net income of -$27.4M. Notably, DexCom's price-to-earnings ratio is 47.83x while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.39x versus 0.84x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 13.54% compared to DexCom's net margin of 14.25%. DexCom's return on equity of 30.96% beat Insulet's return on equity of 49.55%.

DexCom has a consensus price target of $95.68, signalling upside risk potential of 20.51%. On the other hand Insulet has an analysts' consensus of $291.63 which suggests that it could grow by 8.65%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Insulet quarterly revenues of $543.9M. DexCom's net income of $134.6M is higher than Insulet's net income of $77.5M. Notably, DexCom's price-to-earnings ratio is 47.83x while Insulet's PE ratio is 45.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.39x versus 10.34x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of 13.54% compared to DexCom's net margin of -2.74%. DexCom's return on equity of 30.96% beat QuidelOrtho's return on equity of -47.52%.

DexCom has a consensus price target of $95.68, signalling upside risk potential of 20.51%. On the other hand QuidelOrtho has an analysts' consensus of $50.29 which suggests that it could grow by 7.42%. Given that DexCom has higher upside potential than QuidelOrtho, analysts believe DexCom is more attractive than QuidelOrtho.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.079, suggesting its less volatile than the S&P 500 by 92.104%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than QuidelOrtho quarterly revenues of $727.1M. DexCom's net income of $134.6M is higher than QuidelOrtho's net income of -$19.9M. Notably, DexCom's price-to-earnings ratio is 47.83x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.39x versus 1.13x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 13.54% compared to DexCom's net margin of -9.53%. DexCom's return on equity of 30.96% beat Tandem Diabetes Care's return on equity of -47.23%.

DexCom has a consensus price target of $95.68, signalling upside risk potential of 20.51%. On the other hand Tandem Diabetes Care has an analysts' consensus of $51.00 which suggests that it could grow by 36.53%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.148%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Tandem Diabetes Care quarterly revenues of $244M. DexCom's net income of $134.6M is higher than Tandem Diabetes Care's net income of -$23.3M. Notably, DexCom's price-to-earnings ratio is 47.83x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.39x versus 2.86x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.